These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35448201)

  • 41. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M
    Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
    J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
    Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
    Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
    Guru Murthy GS; Atallah E
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):346-350. PubMed ID: 37363977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of front line chronic lymphocytic leukemia.
    Kutsch N; Fink AM; Fischer K
    Am J Hematol; 2022 Nov; 97 Suppl 2():S3-S10. PubMed ID: 36125035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Smolej L
    Br J Haematol; 2021 May; 193(4):723-726. PubMed ID: 33216352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
    Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
    Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
    Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Lampson BL; Brown JR
    Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
    Brumbaugh Paradis H; Alter D; Llerandi D
    Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
    Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
    Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.